Immuno-Oncology

MabSpace has established a pipeline of therapeutic antibodies targeting various compoents of the tumor microenvironment. The lead asset is a second generation blocking PD-L1 ab with unique pH-dependent antigen binding and recycling properties. To enable combination therapy, MabSpace has developed antibodies targeting angiogeneic receptor VEGFR2, agonist antibody targeting OX40 for enhancing T cell activities and suppressing regulatory T cells, as well as antibody targeting CSF1R for the inhibition of immune suppresiion mediated by tumor associated macrophage. In addition, MabSpace has ongoing projects targeting dendritic cells and other checkpoint inhibitors.